Evidence map›Paper›PMID 39072634›Full record

ArticleAntimicrobial agents and chemotherapy2024

ABD-3, the confluence of powerful antibacterial modalities: ABDs delivering and expressing

Geeta Ram, LiTing Chiu, Somrita Dey, Hope F Ross, Michael Cammer, Richard P Novick

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Geeta RamDepartments of Medicine and Microbiology, NYU Grossman School of Medicine, New York, New York, USA.ORCID 0000-0002-1851-3790
LiTing ChiuDepartments of Medicine and Microbiology, NYU Grossman School of Medicine, New York, New York, USA.
Somrita DeyDepartments of Medicine and Microbiology, NYU Grossman School of Medicine, New York, New York, USA.
Hope F RossDepartments of Medicine and Microbiology, NYU Grossman School of Medicine, New York, New York, USA.
Michael CammerMicroscopy Core, Division of Advanced Research Technologies, NYU Grossman School of Medicine, New York, New York, USA.
Richard P NovickDepartments of Medicine and Microbiology, NYU Grossman School of Medicine, New York, New York, USA.ORCID 0000-0003-4418-7893

Funding

Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ADRIANA HEGUY · 1985 to 2026
$83.1M
Converting staphylococcal pathogenicity islands from malevolence to benevolenceR01AI139613 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI NOVICK, RICHARD P. · 2019 to 2023
$4.0M
HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) 1R01-AI139613NCI NIH HHS P30 CA016087NIAID NIH HHS R01 AI139613
6 · The paper itself

Abstract

In response to the antimicrobial resistance crisis, we have developed a powerful and versatile therapeutic platform, the Antibacterial Drone (ABD) system. The ABD consists of a highly mobile staphylococcal pathogenicity island re-purposed to deliver genes encoding antibacterial proteins. The chromosomally located island is induced by a co-resident helper phage, packaged in phage-like particles, and released in very high numbers upon phage-induced lysis. ABD particles specifically adsorb to bacteria causing an infection and deliver their DNA to these bacteria, where the bactericidal cargo genes are expressed, kill the bacteria, and cure the infection. Here, we report a major advance of the system, incorporation of the gene encoding a secreted, bactericidal, species-specific lytic enzyme, lysostsphin. This ABD not only kills the bacterium that has been attacked by the ABD, but also any surrounding bacteria that are sensitive to the lytic enzyme which is released by secretion and by lysis of the doomed cell. So while the killing field is thus expanded, there are no civilian casualties (bacteria that are insensitive to the ABD and its cargo protein(s) are not inadvertently killed). Without amplifying the number of ABD particles (which are not re-packaged), the expression and release of the cargo gene's product dramatically extend the effective reach of the ABD. A cargo gene that encodes a secreted bactericidal protein also enables the treatment of a mixed bacterial infection in which one of the infecting organisms is insensitive to the ABD delivery system but is sensitive to the ABD's secreted cargo protein.

Indexed as

Anti-Bacterial AgentsLysostaphinBacteriophagesGenomic IslandsStaphylococcus aureusAnti-Bacterial AgentsLysostaphinantibacterialbacteriophage assemblyexperimental therapeuticslysostaphinMRSAStaphylococcus

Identifiers

PMID39072634
PMCPMC11373205

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.